Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Impax Laboratories Confirms Patent Challenge Relating to RENVELA®, 2.4 g and 0.8 g (For Suspension)
Impax Laboratories Confirms Patent Challenge Relating to RENVELA®, 2.4 g and 0.8 g (For Suspension)
Impax Laboratories Confirms Patent Challenge Relating to RENVELA®, 2.4 g and 0.8 g (For Suspension)
Submitted by
admin
on July 3, 2010 - 10:06am
Source:
Yahoo/BusinessWire
News Tags:
Impax Labs
Genzyme
Renvela
chronic kidney disease
Headline:
Impax Laboratories Confirms Patent Challenge Relating to RENVELA®, 2.4 g and 0.8 g (For Suspension)
Do Not Allow Advertisers to Use My Personal information
